THE ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST EVER BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS SPECIALIST (BCBBS) CERTIFICATION
THE ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST EVER BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS SPECIALIST (BCBBS) CERTIFICATION
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA) is launching a new Board Certification program focused on biologics and biosimilars. This is the first and only accredited board certification in the biologics and biosimilars arena.
紐約， 2022年12月6日 /PRNewswire/ — 醫學事務認證委員會（ACMA）正在啓動一項新的董事會認證計劃，重點是生物製劑和生物仿製藥。這是生物製劑和生物仿製藥領域的第一個也是唯一一個獲得認證的董事會認證。
The Board-Certified Biologics and Biosimilars Specialist (BCBBS) program will accredit, and board certify healthcare professionals such as pharmacists (PharmDs), MDs, PhDs, and Medical Affairs/MSL professionals. With recent guidelines from Food and Drug Administration (FDA) and Heads of Medicines' Agencies (HMA) Biosimilar Working Group in Europe addressing biosimilars interchangeability, the need for education among the medical and scientific community is vital.
董事會認證的生物製劑和生物仿製藥專家（BCBBS）計劃將對藥劑師（PharmD）、醫學博士、博士和醫學事務/MSL 專業人員等醫療保健專業人員進行認證和董事會認證。根據美國食品藥品監督管理局（FDA）和藥品機構負責人（HMA）生物仿製藥工作組最近發佈的指導方針 歐洲 在生物仿製藥互換性方面，醫學和科學界的教育需求至關重要。
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS CERTIFICATION
醫學事務認證委員會 (ACMA) 制定了首個獲得委員會認證的生物製劑和生物仿製藥認證
William Soliman, Ph.D., BCMAS, ACMA Founder and CEO, said, "The role that biologics and biosimilars play in the treatment of various chronic diseases is growing rapidly. Helping both the healthcare and life sciences industry better understand appropriate clinical use of biologics and biosimilars will be key to successful long-term patient outcomes."
威廉·索利曼，ACMA創始人兼首席執行官BCMAS博士說：“生物製劑和生物仿製藥在治療各種慢性病中所起的作用正在迅速增長。幫助醫療保健和生命科學行業更好地瞭解生物製劑和生物仿製藥的適當臨床用途，將是患者取得成功長期療效的關鍵。”
Currently, biologics and biosimilars board certification does not exist in the industry. The BCBBS certification will cover important topics such as regulatory and scientific concepts for biologics, real-world evidence, economic considerations, FDA resources including the Purple Book Database, and the future outlook on biosimilars. The program is self-paced and online to enable learners from around the world to enroll.
目前，該行業不存在生物製劑和生物仿製藥委員會認證。BCBBS認證將涵蓋重要主題，例如生物製劑的監管和科學概念、現實世界的證據、經濟考慮、包括紫皮書數據庫在內的FDA資源以及生物仿製藥的未來展望。該課程是自定進度的在線課程，使來自世界各地的學習者都能註冊。
As analysts predict, the global biologics and biosimilars market will continue to grow to be a critical part of the healthcare industry. The expansion of biologic treatment options through market entrance of biosimilars across several therapeutic areas offer multiple advantages that will ultimately benefit patients and the overall healthcare delivery system. Understanding biologics and biosimilars in the medical and scientific community will help not only accelerate potential development of new treatments through advanced biotechnology capabilities.
正如分析師所預測的那樣，全球生物製劑和生物仿製藥市場將繼續增長，成爲醫療保健行業的關鍵部分。通過在多個治療領域進入生物仿製藥市場，擴大生物治療選擇具有多重優勢，最終將使患者和整個醫療保健提供系統受益。瞭解醫學和科學界的生物製劑和生物仿製藥不僅有助於通過先進的生物技術能力加速新療法的潛在開發。
About the Accreditation Council for Medical Affairs (ACMA) The ACMA is a global organization providing award-winning solutions for certification, training, analytics, and insights to support the healthcare and life sciences industries. From Medical Affairs to Market Access, Managed Care, and Market Research, ACMA is the standard in the industry for certifying and credentialing prior authorization and medical affairs professionals in over 80+ countries. To learn more, visit medicalaffairsspecialist.org.
關於醫學事務認證委員會 (ACMA)ACMA 是一家全球性組織，爲認證、培訓、分析和洞察提供屢獲殊榮的解決方案，以支持醫療保健和生命科學行業。從醫療事務到市場準入、管理式醫療和市場研究，ACMA 是 80 多個國家/地區對事先授權和醫療事務專業人員進行認證和認證的行業標準。要了解更多信息，請訪問medicalaffairsspecialist.。
SOURCE Accreditation Council for Medical Affairs (ACMA)
來源：醫學事務認證委員會 (ACMA)